123 related articles for article (PubMed ID: 24694004)
1. Molecular modeling studies and comparative analysis on structurally similar HTLV and HIV protease using HIV-PR inhibitors.
Selvaraj C; Singh P; Singh SK
J Recept Signal Transduct Res; 2014 Oct; 34(5):361-71. PubMed ID: 24694004
[TBL] [Abstract][Full Text] [Related]
2. Molecular insights on analogs of HIV PR inhibitors toward HTLV-1 PR through QM/MM interactions and molecular dynamics studies: comparative structure analysis of wild and mutant HTLV-1 PR.
Selvaraj C; Singh P; Singh SK
J Mol Recognit; 2014 Dec; 27(12):696-706. PubMed ID: 25319617
[TBL] [Abstract][Full Text] [Related]
3. Molecular insights of protein contour recognition with ligand pharmacophoric sites through combinatorial library design and MD simulation in validating HTLV-1 PR inhibitors.
Selvaraj C; Omer A; Singh P; Singh SK
Mol Biosyst; 2015 Jan; 11(1):178-89. PubMed ID: 25335799
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
Kuhnert M; Steuber H; Diederich WE
J Med Chem; 2014 Jul; 57(14):6266-72. PubMed ID: 25006983
[TBL] [Abstract][Full Text] [Related]
5. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
6. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
Kar P; Lipowsky R; Knecht V
J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
[TBL] [Abstract][Full Text] [Related]
7. Comparative molecular dynamics study of dimeric and monomeric forms of HIV-1 protease in ligand bound and unbound state.
Padariya M; Kalathiya U
Gen Physiol Biophys; 2017 Apr; 36(2):141-154. PubMed ID: 27921997
[TBL] [Abstract][Full Text] [Related]
8. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells.
Demir A; Oguariri RM; Magis A; Ostrov DA; Imamichi T; Dunn BM
Antivir Ther; 2012; 17(5):883-92. PubMed ID: 22436331
[TBL] [Abstract][Full Text] [Related]
9. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.
Rücker P; Horn AH; Meiselbach H; Sticht H
J Mol Model; 2011 Oct; 17(10):2693-705. PubMed ID: 21279524
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the molecular dynamics and calculated binding free energies for nine FDA-approved HIV-1 PR drugs against subtype B and C-SA HIV PR.
Ahmed SM; Kruger HG; Govender T; Maguire GE; Sayed Y; Ibrahim MA; Naicker P; Soliman ME
Chem Biol Drug Des; 2013 Feb; 81(2):208-18. PubMed ID: 23017010
[TBL] [Abstract][Full Text] [Related]
12. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
Towler EM; Gulnik SV; Bhat TN; Xie D; Gustschina E; Sumpter TR; Robertson N; Jones C; Sauter M; Mueller-Lantzsch N; Debouck C; Erickson JW
Biochemistry; 1998 Dec; 37(49):17137-44. PubMed ID: 9860826
[TBL] [Abstract][Full Text] [Related]
15. Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.
Leonis G; Czyżnikowska Ż; Megariotis G; Reis H; Papadopoulos MG
J Chem Inf Model; 2012 Jun; 52(6):1542-58. PubMed ID: 22587384
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT
Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683
[TBL] [Abstract][Full Text] [Related]
17. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
Li D; Liu MS; Ji B; Hwang KC; Huang Y
Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
19. Exploring the antiviral activity of juglone by computational method.
Vardhini SR
J Recept Signal Transduct Res; 2014 Dec; 34(6):456-7. PubMed ID: 24846583
[TBL] [Abstract][Full Text] [Related]
20. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
